Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

Completed · Phase 1

Conditions studied: Neuroblastoma

In brief

RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.

Key facts

Study ID

NCT00002748

Run by

St. Jude Children's Research Hospital

People needed

38

Starts

1991-12-01

Expected to finish

2007-08-01

Last updated by the study team

2011-10-04

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.